Cytomegalovirus co-infection with HIV in children and adolescents on antiretroviral therapy in Abuja, Nigeria by Okechukwu, A.A. & Thairu, Y.




Okechukwu et al. Afr. J. Clin. Exper. Microbiol. 2020; 21 (1): 36 - 44                                 https://www.afrjcem.org 
African Journal of Clinical and Experimental Microbiology ISSN 1595-689X              Jan 2020 Vol.21 No.1 
AJCEM/1969: https://www.ajol.info/index.php/ajcem                                                   
Copyright AJCEM 2020: https://dx.doi.org/10.4314/ajcem.v21i1.5                                                    
Original Article                   Open Access 
Cytomegalovirus co-infection with HIV in children and adolescents 
on antiretroviral therapy in Abuja, Nigeria 
 
1*Okechukwu, A. A., and 2Thairu, Y.  
 
1Deparment of Paediatrics, University of Abuja Teaching Hospital, Gwagwalada, Abuja, Nigeria 
2Department of Microbiology, University of Abuja Teaching Hospital, Gwagwalada, Abuja, Nigeria 
Correspondence to: nebokest@yahoo.com; +2348036719906 
Abstract: 
 
Background: Cytomegalovirus (CMV) co-infection with human immunodeficiency virus (HIV) is known to 
accelerate HIV disease progression. It has the potential of being a killer disease or a silent lifetime companion in 
HIV patients. There is dearth of information on CMV prevalence among HIV infected children and adolescents in our 
environment. We therefore conducted this study to determine its sero-prevalence, and risk factors for co-infection 
among HIV infected children and adolescents on highly active antiretroviral therapy (HAART) in our center.  
Method:  A descriptive cross sectional study of HIV-infected children and adolescents aged 2 months to 18 years 
on HAART was conducted over a 6 month period between October 2017 and March 2018 in our health facility. 
Blood samples of subjects were screened for CMV IgM using commercial test kits. Biodata of subjects, CD4 cell 
count, and viral load were collected into a designed proforma, and statistical analysis was done with SPSS version 
22.0. 
Result: A total of 161 HIV-infected children and adolescents were recruited, 103 (64.0%) were males, 83 (51.6%) 
were between the ages of 5 and <10 years, 113 (70.2%) were from lower socio-economic class, and 138 (85.7%) 
were on 1st line HAART.  Of the 17 (10.6%) subjects positive for CMV IgM, 3 (17.6%) were less than 5 years old, 
11 (64.7%) were between the ages of 5-10 years, and none was older than 15 years. Univariate analysis showed 
significant differences in the mean age, weight, length/height, and systolic blood pressure between CMV IgM 
positive and negative patients (p<0.05), but no significant difference in gender, socioeconomic class, types of 
antiretroviral drugs, CD4 cell count, and viral load (p>0.05). Multivariate analysis however did not show any 
significant difference in age, weight, length/height, and systolic blood pressure.                      
Conclusion: The prevalence of active CMV infections among HIV infected children and adolescents on HAART in 
our centre is high. Low CD4 cell count and high viral load were not associated with active CMV disease, and no risk 
factor for co-infection was also identified. Identifying those with primary/active infection will be necessary for 
possible treatment with anti-herpes drugs before development of reactivated CMV disease. 
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Abstrait:                       
Contexte: On sait que la co-infection par le cytomégalovirus (CMV) et le virus de l’immunodéficience humaine 
(VIH) accélère la progression de la maladie. Il a le potentiel d'être une maladie mortelle ou un compagnon 




silencieux à vie chez les patients VIH. Il existe peu d'informations sur la prévalence du CMV chez les enfants et les 
adolescents infectés par le VIH dans notre environnement. Nous avons donc mené cette étude pour déterminer sa 
séroprévalence et les facteurs de risque de co-infection chez les enfants et les adolescents infectés par le VIH sous 
traitement antirétroviral hautement actif (HAART) dans notre centre.                                
Méthode: Une étude transversale descriptive des enfants et adolescents infectés par le VIH et âgés de 2 mois à 18 
ans sous multithérapie a été menée sur une période de 6 mois entre octobre 2017 et mars 2018 dans notre 
établissement de santé. Des échantillons de sang de sujets ont été testés pour l'IgM de CMV en utilisant des kits de 
test commerciaux. Les données biologiques des sujets, le nombre de cellules CD4 et la charge virale ont été 
recueillis dans un formulaire conçu à cet effet et une analyse statistique a été réalisée avec SPSS version 22.0. 
Résultat: 161 enfants et adolescents infectés par le VIH ont été recrutés, dont 103 (64,0%) étaient des hommes, 
83 (51,6%) étaient âgés de 5 à moins de 10 ans, 113 (70,2%) étaient issus de milieux socio-économiques 
inférieurs. et 138 (85,7%) suivaient la multithérapie de première ligne. Sur les 17 (10,6%) sujets positifs pour 
l'IgM du CMV, 3 (17,6%) avaient moins de 5 ans, 11 (64,7%) étaient âgés de 5 à 10 ans et aucun n'avait plus de 
15 ans. Une analyse univariée a montré des différences significatives dans l'âge moyen, le poids, la taille / taille et 
la pression artérielle systolique entre les patients positifs et négatifs pour IgM anti-CMV (p<0,05), mais aucune 
différence significative entre le sexe, la classe socio-économique, les types de médicaments antirétroviraux et les 
cellules CD4 nombre et charge virale (p>0,05). L'analyse multivariée n'a cependant montré aucune différence 
significative d'âge, de poids, de taille / taille et de pression artérielle systolique.                 
Conclusion: La prévalence des infections à CMV actives chez les enfants et les adolescents infectés par le VIH 
sous HAART dans notre centre est élevée. Un faible nombre de cellules CD4 et une charge virale élevée n'étaient 
pas associés à la maladie à CMV active et aucun facteur de risque de co-infection n'a également été identifié. 
Identifier les personnes présentant une infection primaire / active sera nécessaire pour un traitement éventuel avec 
des médicaments anti-herpès avant le développement d'une maladie à CMV réactivée. 
Mots-clés: CMV; HIV; co-infection; anti-rétroviral; Enfants; les adolescents 
Introduction: 
 
 Cytomegalovirus also known as human 
herpes virus (HHV) 5 is one of the eight HHVs, 
belonging to beta herpesvirus subfamily. 
Infection is ubiquitous, and generally asymp- 
tomatic in healthy children and adults. Infants 
usually acquire the infection while in the 
uterus, during passage through the birth canal, 
or through breast milk. Young children are 
frequently infected by contaminated saliva 
when sucking and sharing toys. The virus can 
also be contacted through respiratory routes, 
pharyngeal secretions, tears, urine, faeces, 
seminal and vaginal fluids, during blood 
transfusion, organ transplant, or through 
sexual contact (1). Infection is largely contact- 
ed during childhood or during sexual activities 
in human population worldwide with some 
regional variations (1). Following primary 
infection, the virus becomes latent in a few 
cells in its episomal form (2). Reactivation with 
viral shedding occurs when immunity is 
compromised as seen in HIV co infection (2). 
 CMV is widely recognized as an 
opportunistic pathogen causing severe oppor- 
tunistic infections in immuno-compromised 
individuals which generally manifests as 
retinitis with high tendency to cause rapid loss 
of vision, chronic crippling diarrhea, central 
nervous system diseases and sudden loss of 
neurologic function, and pneumonia (3, 4). 
CMV active infection might be a marker of 
extremely severe immunosuppression that can 
ultimately lead to a fatal outcome in immuno- 
compromised individual. Primary CMV infection 
occurs in a previously sero-negative individual 
and can be a potential killer in such individual, 
whereas secondary infection which is 
intermittent excretion of the virus in the 
presence of host immunity may be due to 
either reactivation of an endogenous virus or 
exposure to a new virus strain from an 
exogenous source. (5). Hence the presence of 
the IgM antibodies may be due to 
primary/active infection or re-infection (6).  
 Persistent immune activation is 
hallmark of human immunodeficiency virus 
infection, and in co-infected individual, CMV-
induced T cell activation potentially contributes 
to increased HIV disease progression (7). The 
two viruses while infecting a number of similar 
cell types such as the endothelium of blood 
vessels, mononuclear cells, white blood cells, 
and epithelial cells, also interact through 
transactivation, secretion of cytokines that 
reactivate provirus, or increase in HIV tropism 
through CMV expression of receptor analogues 
or by formation of pseudoviruses (8). HIV 
infection induces immunosuppression through 
depletion of CD4 cell count with increasing 
CMV reactivation, the reactivation promote HIV 
replication through a complex interaction with 
the long terminal repeat region, transactivation 
of proviral HIV, release of inflammatory 
cytokines and chemokines, and up-regulation 
of CCR5 expression in central memory T cells 
(9-11). During the era of antiretroviral therapy 
(ART), accumulated data in adults suggests 
that  CMV  co-infection  with   HIV  contributes  




significantly to the accelerated HIV disease 
progression and development of non AIDS-
defining comorb- idities (12-17). The complex 
interplay of these two chronic viral infections 
continues to be potentially significant 
especially in highly endemic area of sub-
Saharan Africa, where both viruses are 
endemic (18).     
 In industrialized countries such as USA, 
Australia and Europe, CMV sero-prevalence 
among adult population is between 36 and 
77%, in contrast to highly endemic areas of 
sub-Saharan Africa, where sero-prevalence 
approaches 100% (19). There is serological 
evidence of CMV infection in almost two thirds 
of infants from African origin by 3 months of 
age, and 85% are infected by a year (20). 
Among HIV-infected children in Africa, the 
majority are co-infected with CMV by their first 
birthday (20) and almost all by the time they 
reach their teens, in contrast to what is seen in 
industrialized nations (7, 21).     
 Antibody testing can be used to 
determine recent or past exposure to CMV 
infection. The first antibody to develop in 
response to CMV infection is IgM. This 
develops within a few days following primary 
infection. While CMV IgM remains detectable 
for six to nine months in the blood, medium to 
high levels of CMV IgM can be detected during 
the first three months of a primary infection. 
IgM is also detected during secondary 
infections either as re-activation or re-
infection. By assessing the presence of IgM in 
a sample, active CMV infection can be 
ascertained. This study was therefore condu- 
cted to determine the prevalence of active CMV 
infection in HIV infected children and 
adolescents on ART in our health facility. The 
study also aimed to determine the risk factors 
for acquisition of the CMV, and the effects of 
co-infection on CD4 cell count and viral load of 
HIV patients.  
 
Materials and method: 
 
Study setting and design 
 A cross sectional hospital based study 
was conducted at the Paediatric Out-patient 
Special Treatment Clinic (POSTC) of the 
University of Abuja Teaching Hospital (UATH) 
over a 6 months period from October 2017 to 
March 2018. POSTC is an arm of out-patient 
service area of department of paediatrics 
where HIV infected children/adolescents and 
exposed babies are seen and followed up for 
treatment/monitoring. The clinic is opened for 
services from Monday-Friday, and from 7.30 
am to 4 pm. UATH is a 350 bed capacity 
referral hospital, sub-serving the people of 
Federal Capital Territory (FCT) Abuja and 
neighbouring states of Nassarawa, Kogi, 
Kaduna, and Niger States.  It is one of the first 
centers since 2005 to start offering free 
HIV/AIDS services in the country through the 
President Emergency Plan for AIDS Relief 
(PEPFAR) and the Federal Government of 
Nigeria (FGN).  
 
Subjects     
 The subjects were paediatric patients’ 
2 months to 18 years old tested positive for 
HIV by either serological method or by 
polymerase chain reaction (PCR) test and 
started on anti retroviral therapy (ARV) 
therapy. Consecutive eligible children and 
adolescents attending the POSTC were 
recruited and subsequently enrolled into the 
study after parents/caregivers provided written 
informed consent and children 7 years and 
above provided assent for the study. Inclusion 
criteria for the study were; HIV infected 
children and adolescents aged 2 months to 18 
years on ARV therapy, parents/caregivers and 
older children accepting to be part of the 
study. Exclusion criteria included those 
unwilling to participate in the study, and 
exposed uninfected infants. Ethics clearance 
was obtained from the ethics committee of the 
hospital before the commencement of the 
study. 
 
Clinical data and sample collection 
 Clinical and physical examination were 
carried out after enrollment by the attending 
physician. The demographic characteristics of 
the subjects were collected which included age, 
gender, religion, and socio economic statue 
(SES) of the parents. Using a vaccutainer 
needle, three milliliters (3 mls) of venous blood 
was collected from each subject and 
transported to the laboratory for analysis. In 
addition, the weight, blood pressure, CD4 cell 
count, and viral loads (VL) were retrieved from 
the patient’s information record if done within 




 The serum was separated by 
centrifugation at 3500 rpm for 5 minutes and 
refrigerated (2-8˚C) until analysis was done. 
At the time of analysis, the serum was 
carefully removed using a fine bore pipette to 
avoid extracting red cells and the test device 
removed from the sealed pouch. Screening for 
CMV IgM was done using commercial fortress 
diagnosticsR (CMV IgM) ELISA immunoassays 




kits. The clinical sensitivity and specificity of 
the Cyto IgM ELISA kits was 99.6% on plasma 
and sera. The cut-off optical density (O.D) was 
obtained in accordance with the manufacturer’s 
instructions; the CMV index of the samples was 
calculated by dividing the O.D value of each of 
the samples with the obtained Cut-off O.D 
values. OD interpretation was CMV index of 
<0.90 as negative and CMV index of 1.0 and 
above as positive.     
 CD4 cell count was measured using 
automated Partec Cyflow easy count kit (Partec 
code no. 05-8401 Western Germany), Viral 
load (VL) measurement was performed with 
Roche Smp/prep/cobs Taqman 96, USA, and 
Seca beam weighing scale was used to 




 Data analysis was done using SPSS 
version 22.0, and percentage, means and 
standard deviations were calculated for the 
variables. The test for association was done 
using student t-test for continuous variables 
and Chi-square or Fisher’s exact test for 
categorical variables where applicable. 
Multivariate logistic model was used to 
determine associated risk factors of CMV co-
infection with HIV, unadjusted and adjusted 
odds ratio (OR) were reported, and p value of 
<0.05 was considered significant.  
Results: 
 
 Table 1 shows the demographic and 
clinical characteristics of the study population. 
Of a total of 161 HIV infected children and 
adolescents screened for CMV IgM antibody, 
103 (64.0%) were males, 83 (51.6%) were 
between the ages of 5-10 years, 110 (68.3%) 
were Christians, 113 (70.2%) were from low 
socio-economic class and 138 (85.7%) were on 
1st line HAART. The mean body weight, CD4 
cell count and VL were 30.0±12.4 kg, 
979.5±457.7 cells/μl, and 9,136.1±306.0 
copies/ml. There was no significant difference 
in the demographic characteristics between the 
male and female populations (p>0.05 for all 
the variables).  
 Table 2 shows the association of CMV 
IgM antibody and the co-variables. Seventeen 
(10.6%) of the 161 patients screened tested 
positive for the IgM antibody, while 144 
(89.4%) were negative. Three (17.6%) of 
those tested positive were less than 5 years, 
11 (64.7%) were between the ages of 5 and 
<10 years, and none was older than 15 years. 
On univariate analysis, significant difference 
was observed in mean age (p=0.025), body 
weight (p=0.004), length/height (p=0.039), 
and systolic blood pressure (p=0.001) between 
those who tested positive and negative for the 
CMV IgM. On multivariate logistic regression, 
none of the associated factors (age, body 
weight, length/height, and systolic blood 
pressure) showed significant association with 
CMV infection (p>0.05) (Table 3).  
 Although there were more male 
subjects (10, 58.8%), subjects in the age 
range of 5-<10 years (11, 64.7%), Christians 
(9, 52.9%), subjects from low socio-economic 
class (16, 94.1%), and subjects on 1st line 
ART (15, 88.2%) who tested positive for CMV 
IgM, the difference was not significantly 
different from CMV IgM negative subjects 
(p>0.05 for all the variables). Similarly, there 
were no statistically significant differences for 
other parameters;  CD4 cell count, VL, BMI, 
ART duration, and diastolic blood pressure 
between those positive and negative for CMV 
IgM (p>0.05 for all variables).    
 Table 4 depicts the different values of 
CD4 cell count and VL in relation to CMV IgM 
positivity and negativity. Only 1 (5.9%) patient 
with CD4 cell count of <200 cells/μl and 2 
(11.8%) with VL of >1000 copies/ml tested 
positive for CMV IgM. There was no significant 
difference in the values of CD4 cells and VL 
between CMV IgM positive and negative 
patients (p>0.05).  
 
Discussion: 
 The prevalence of active or primary 
CMV infection in HIV infected children and 
adolescents on highly active anti-retroviral 
therapy (HAART) in this study, was 10.6%. 
This was  comparable to 13% among HIV 
infected adolescents and adults from Kano by 
Musa et al., (22), 9.5% among AIDS patients 
from India by Basawaraju et al., (23) and 
11.4% among infected prison inmates by 
Neusa et al., (24) in Brazil. The rate in our 
study  is however much lower than 58.3% 
reported among HIV-infected infants initiated 
on ART in Cameroun by Kfutwah et al.,(26), 
28% by Oladipo et al., (27) among blood 
donors in Nigeria, and 14% among HIV 
patients by Tsertsvadze et al., (28). The 
prevalence rates of 3.5% (29), 4.5% (30), 
6.6% (31), 7.0% (32), 8.1% (33), and 8.4% 
(25) from various studies in Nigeria, Qatar, 
and Kenya were lower than the 10.6% 
recorded in this study. Although most of these 
referenced studies were from adult population, 
pregnant women and blood donors, with only 
two from HIV children and adolescents, the 





Table 1: Demographic and clinical characteristics of HIV-infected children and adolescents in University of Abuja 
Teaching Hospital, Gwagwalada, Abuja, Nigeria   








No of subjects 103 (64.0) 58 (36.0) 161 (100) 
 
0.64 
Age group (years)     
 <5 11(10.7) 2 (3.4) 13 (8.1)  











Religion     
 Christianity 74 (71.8) 36 (62.1) 110 (68.3)  
 Islam 29 (28.2) 22 (37.9) 51 (31.7) 0.201 
Socio-economic class     
 High 11 (10.7) 5 (8.6) 16(9.9)  
 Middle 22 (21.4) 10 (17.2) 32(19.9)  
 Low 
1st or 2nd line ARVT 
 1st Line 
 2nd Line 
 
ARVT duration (years)* 
 
Wt, CD4 and Viral Load* 
 Weight (kg) 
 CD4 (cells/μl) 














































 ARVT = Antiretroviral therapy; Wt = weight; *=mean values; CD = clusters of differentiation  
 
Table 2: Clinical variables in HIV-infected children and adolescents with CMV co-infections in University of Abuja 
Teaching Hospital, Gwagwalada, Abuja, Nigeria 
 
ARV= antiretroviral therapy, *= mean values; ** = significant difference; X2 = Chi square value 
















X2 p value 
 
 
 Subjects 17 (10.6)  144 (89.4) 161 (100)  
 
 
 Age Group (years)      
 <5 3 (17.6) 10 (6.9) 13 (8.1) 5.558 0.135 





























 Religion      
 Christianity 9 (52.9) 101 (70.1) 110 (68.3) 2.078 0.149 
 Islam 8 (47.1) 43 (29.9) 51 (31.7)   
 Socio-economic class      
 High 0 16 (11.1) 16 (9.9) 0.912 0.634 
 Middle 1 (5.9) 31 (21.5) 32 (19.9)   
 Low 
 Types of ARV Drugs 
 1st line 
 2nd line 
 
 Co-variables* 
 Age (years) 
 ARV duration (years) 
 Weight (kg) 
 Length/height (cm) 
 BMI (kg/m2) 
 Systolic BP (mmHg) 
 Diastolic BP (mmHg) 
 CD4 (cells/μl)) 
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Table 3: Multivariate logistic regression of associated risk factors for CMV infection in HIV-infected children and 
adolescents in University of Abuja Teaching Hospital, Gwagwalada, Abuja, Nigeria 
 
Variables Unadjusted  OR  
(95 % CI) 






0.7 - 0.975 0.017 
0.545 












0.95 - 0.99 0.049 
0.501 
0.98 - 1.146 0.094 
0.924 
Systolic Blood Pressure 
Constant 




0.88 - 1.015 0.118 
0.924 
 OR = odd ratio; CI = confidence interval 
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Table 4: CD4 cell count and Viral Load of HIV infected children and adolescents with CMV IgM in University of Abuja 





CMV IgM positive 
(%) 
 
CMV IgM negative 
(%) 
Total (%) X2 p value 
CD4 cell count (cells/μl)      
 <200 1 (5.9) 2 (1.4) 3 (1.9) 2.631 0.268 
 200-500 1 (5.9) 22 (15.3) 23 (14.3)   
 > 500 15 (88.2) 120 (83.3) 135 (83.8)   
Viral Load (copies/ml)      
 < 20 10 (58.8) 65 (45.1) 75 (46.6) 1.389 0.499 
 20 - 1000 5 (29.4) 48 (33.3) 53 (32.9)   
 > 1000 
 
2 (11.8) 31 (21.5) 33 (20.5)   
CD = clusters of differentiation; CMV = cytomegalovirus; IgM = immunoglobulin M; X2 = Chi square 
 
differences however might not be unrelated to 
geographical locations of the studies, study  
populations, ethnic, social, cultural, and 
economic differences, and different sensitivity 
of the IgM screening tests used (34). 
 The high prevalence of active CMV 
infection in HIV children and adolescents in our 
study could signify either high level of primary 
infection or new strain of reactivated 
infections. This should be worrisome in this 
highly endemic area where vaccines for CMV 
have not yet been developed. However, the 
fact that all the patients in this study were on 
HAART with no clinical evidences of severe 
immune suppression such as retinitis, chronic 
crippling diarrhea, or other features of AIDS 
from CMV co-infection may suggest other 
associated factor(s) in the etiology of co-
infection. Akinbami et al., (29) and Klatt and 
Shibata (36), however attributed such clinical 
manifestations of co-infection to reactivation of 
previous CMV infection rather than primary 
infection.  
 Our study showed non-statistically 
significant higher prevalence rate of CMV IgM 
in the male than female subjects, which is 
similar to the observations of Ojide et al., (31) 
and Fowotade et al., (35) among their HIV-
infected adults cohort. Musa et al., (22) 
however had a contrary observation in Kano 
where they reported more female patients 
living with HIV having significantly higher CMV 
IgM than their male counterparts (8.7% vs 
4.3%, p<0.01) although no reason for such 
finding was proffered. Udeze et al., (37) 
equally found significantly higher primary/ 
active CMV IgM among males than females 
HIV-infected children and adults on ART in 
their study cohort in Ilorin, and attributed such 
findings to more exposure of males to factors 
that lead to re-activation or re-infection of CMV 
in their locality.  
 There was also non-statistically 
significant highest prevalence of CMV IgM 
among subjects in 5-<10 year age group 
(64.7%) when compared to other paediatric 
age groups in this study (p=0.135). This is the 
period when parents usually send their children 
to day care services, nursery or primary 
schools. CMV transmission among children in 




day care centers may be enhanced as a result 
of poor hand hygiene practices and 
overcrowding usually seen in such care centres 
(38). Exposure of children to such centers 
therefore increase the risk of CMV cross 
infection from school mates. Other studies 
however have shown significant association 
between prevalence of active CMV infection 
and other age groups (35, 37). In the study by 
Udeze et al., (37), higher IgM was significantly 
observed among children in age group ≤20 
years (p=0.047) among their HIV cohorts aged 
1 to 70 years on ART studied at Ilorin. The 
authors attributed such significant positive 
findings to the lower level of education and 
engagement in risky sexual behaviours in the 
age group but because the study did not 
separate the children into different paediatric 
age groups, it was difficult to appreciate which 
particular age group among the children had 
the highest prevalence of CMV IgM. CMV 
infection is ubiquitous with primary/active 
infection occurring commonly during childhood 
or adulthood in 4 out of every 5 person above 
35 years old, but the infection is usually very 
mild and generally unrecognized (39).    
 Many previous studies identified low 
socio-economic class (SEC) as a risk factor for 
CMV infection (6,15,17). Our study however 
showed no significant association between low 
SEC and CMV IgM in the children and 
adolescents (p=0.634). Basha et al., (40) 
equally observed no significant association 
between CMV sero-prevalence and SEC 
(p=0.58) in their prospective cohort of non HIV 
Australian children aged 0-15 years. They 
however reported more congenital CMV in 
individuals with high SEC (55%) than the low 
SEC (9%) (p<0.001). Our study shows 
significant association between CMV IgM with 
respect to mean age, mean body weight, 
length/height and mean systolic blood pressure 
in the univariate analysis. These significant 
findings were not surprising considering that 
IgM were seen in younger age groups (none 
seen in >15years), and these variables were 
all age dependent. However on multivariate 
logistic analysis, all these variables were not 
statistically significant. 
 Low CD4 cell count in HIV infected 
person and high VL are indications of poor 
immunity and inadequate viral suppression. 
Although the prevalence of CMV IgM was 
higher among patients with high CD4+ cell 
counts and low VL in our study, this 
surprisingly, was not statistically significant. 
Similar studies in Benin (31) and Ilorin (37) in 
Nigeria, and in Iran (41) also found no 
statistically significant association between 
CD4+ cell count values and prevalence of CMV 
IgM in their study populations, and adduced 
such findings to the effects of ART and 
duration of treatment. Patients in the present 
study had mean CD4 cell count and ART 
treatment duration of 958.6±37.8 cells/μl and 
6.9±3.4 years respectively, indicating 
adequate immune response and long duration 
on ART. Going by the suggestion of Ojide et 
al., (31) and Udeze et al., (37), the good 
immunological response of patients in our 
study and their long duration on ART could 
possibly explain the non-significant association 
between prevalence of CMV IgM and CD4 cell 
count and VL. However, many other studies 
have shown prevalence of CMV IgM to be 
significantly associated with CD4 cell count 
(22, 40, 41). Although significant association 
was observed between CD4 cell count and 
prevalence of CMV IgM among HIV infected 
patients in the study by Musa et al., (22), the 
authors noted that there was no positive 
correlation between CD4 cell count and the 




 Our study reports high prevalence of 
CMV IgM, indicating active/primary CMV 
infection among HIV infected children and 
adolescents on HAART. This prevalence was 
not significantly associated with low CD4 cell 
count, high VL or any risk factor. Identifying 
those with primary/active infection is nec- 
essary for possible treatment with anti-herpes 
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